

10/567012
IAP9 Rec'd PCT/PTO 01 FEB 2005

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT				ATTORNEY DOCKET NO. PR60419USw	SERIAL NO. To be assigned
				APPLICANT Neil Lee SPECTOR et al.	
				FILING DATE Concurrently herewith	GROUP To be assigned 1643

U.S. PATENT DOCUMENTS

Examiner Initials		Patent Number	Issue Date	Name	Class	Subclass	Filing Date If Appropriate
AMH	1.	6,169,091	01/02/2001	COCKERILL et al.			
	2.	6,174,889	01/16/2001	COCKERILL et al.			
	3.	6,207,669	03/27/2001	COCKERILL et al.			
	4.	6,391,874	05/21/2002	COCKERILL et al.			

Continue on page

FOREIGN PATENT DOCUMENTS

		Document Number	Publication Date	Country	Class	Subclass	Translation Yes No
	5.	WO 99/35146	07/15/1999	PCT			X
	6.	WO 01/04111	01/18/2001	PCT			X
	7.	WO 02/02552	01/10/2002	PCT			X
	8.	WO 02/056912	07/25/2002	PCT			X

Continue on page

OTHER DOCUMENTS (Including Author, Title, Journal-Date, Page Number, Etc.)

AMH	9.	Bargmann et al., "Oncogenic activation of the <i>neu</i> -encoded receptor protein by point mutation and deletion," <i>EMBO J</i> (7):2043-2052 (1988).
AMH	10.	Burris, "Dual kinase inhibition in the treatment of breast cancer: Initial experience with the EGFR/ERBB-2 inhibitor lapatinib," <i>The Oncologist</i> 9 Suppl. 3:10-15 (2004).
AMH	11.	Christianson et al., "NH ₂ -terminally truncated HER-2/neu protein: relationship with shedding of the extracellular domain and with prognostic factors in breast cancer," <i>Cancer Research</i> 58(22):5123-5129 (Nov. 1998).
	12.	Colomer et al. "Circulating HER2 extracellular domain and resistance to chemotherapy in advanced breast cancer," <i>Clin. Cancer Research</i> 6(6):2356-2362 (Jun. 2000).
	13.	DiFiore et al., "erbB2 is a potent oncogene when overexpressed in NIH/3T3 cells," <i>Science</i> 237:178-182 (Jul. 1987).
	14.	Harris et al., "Comparison of methods of measuring HER-2 in metastatic breast cancer patients treated with high-dose chemotherapy," <i>J. Clin. Oncol.</i> 19(6):1698-1706 (Mar. 2001).
	15.	Molina et al. "Trastuzumab (Herceptin), a humanized anti-HER2 receptor monoclonal antibody, inhibits basal and activated HER2 ectodomain cleavage in breast cancer cells," <i>Cancer Res.</i> 61(12):4744-4749 (Jun. 2001).
	16.	Molina et al., "NH ₂ -terminal truncated HER-2 protein but not full-length receptor is associated with nodal metastasis in human breast cancer," <i>Clin. Cancer Res.</i> 8(2):347-353 (Feb. 2002).
AMH	17.	Rusnak et al., "The characterization of novel, dual ErbB-2/EGFR, tyrosine kinase inhibitors: potential therapy for cancer," <i>Cancer Res.</i> 61(19):7196-7203 (Oct. 2001).
AMH	18.	Rusnak et al., "The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines <i>in Vitro</i> and <i>in Vivo</i> ," <i>Mol. Cancer Therap.</i> 1(2):85-94 (Dec. 2001).
AMH	19.	Segatto et al., "Different structural alterations upregulate <i>in vitro</i> tyrosine kinase activity and transforming potency of the erbB-2 gene," <i>Mol. Cell. Biol.</i> 8(12):5570-5574 (Dec. 1988).
AMH	20.	Xia et al., "Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways," <i>Oncogene</i> 21(41):6255-6263 (Sep. 2002)
AMH	21.	Xia, "Truncated ErbB2 receptor (p95 ErbB2) is regulated by heregulin through heterodimer formation with ErbB3 yet remains sensitive to the dual EGFR/ErbB2 kinase inhibitor GW572016," <i>x</i> 23(3):646-653 (Jan. 2004).

Continue on page

EXAMINER <i>AMH Harris</i>	DATE CONSIDERED <i>12/09/2007</i>
-------------------------------	--------------------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.

